| Athersys is a biotechnology company that is focused in the field of regenerative medicine. Co.'s MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its primary platform product and is in clinical development. Co.'s existing clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the existing standard of care is limited or inadequate for a number of patients. Co. has a collaboration with HEALIOS K.K., to develop and commercialize MultiStem for the treatment of certain indications in Japan. We show 40 historical shares outstanding datapoints in our ATHX shares outstanding history coverage, used to compute ATHX market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ATHX market cap history over the course of time is important for investors
interested in comparing ATHX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ATHX versus a peer is one thing; comparing
ATHX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ATHX can fluctuate over the course of history.
With this page we aim to empower investors researching ATHX by allowing them to research the ATHX market cap history.